At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Nov 3, 2026 at 06:45 ET
Sophia Genetics reported Q3 2026 revenue of $24.3M, up 25% YoY, beating the $24.0M consensus. GAAP EPS was -$0.24, below the consensus estimate of -$0.20, resulting in an EPS miss. The company guided full-year 2026 revenue to the upper end of its $94M-$96M range and narrowed adjusted EBITDA loss guidance to $29M-$32M, improving from $41.5M in FY 2025.
- Q3 2026 revenue $24.3M, up 25% YoY, above $24.0M consensus
- GAAP EPS -$0.24 vs consensus -$0.20 (miss)
- Adjusted EBITDA loss improved 31% YoY to $6.1M
- Full-year 2026 revenue guided to upper end of $94M-$96M range
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access